These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 31926117)

  • 1. Anti-tumour immune response in GL261 glioblastoma generated by Temozolomide Immune-Enhancing Metronomic Schedule monitored with MRSI-based nosological images.
    Wu S; Calero-Pérez P; Villamañan L; Arias-Ramos N; Pumarola M; Ortega-Martorell S; Julià-Sapé M; Arús C; Candiota AP
    NMR Biomed; 2020 Apr; 33(4):e4229. PubMed ID: 31926117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide.
    Ferrer-Font L; Arias-Ramos N; Lope-Piedrafita S; Julià-Sapé M; Pumarola M; Arús C; Candiota AP
    NMR Biomed; 2017 Sep; 30(9):. PubMed ID: 28570014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-PD-1 Immunotherapy in Preclinical GL261 Glioblastoma: Influence of Therapeutic Parameters and Non-Invasive Response Biomarker Assessment with MRSI-Based Approaches.
    Wu S; Calero-Pérez P; Arús C; Candiota AP
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular imaging coupled to pattern recognition distinguishes response to temozolomide in preclinical glioblastoma.
    Delgado-Goñi T; Julià-Sapé M; Candiota AP; Pumarola M; Arús C
    NMR Biomed; 2014 Nov; 27(11):1333-45. PubMed ID: 25208348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune System-Related Changes in Preclinical GL261 Glioblastoma under TMZ Treatment: Explaining MRSI-Based Nosological Imaging Findings with RT-PCR Analyses.
    Calero-Pérez P; Wu S; Arús C; Candiota AP
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34071393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MRSI-based molecular imaging of therapy response to temozolomide in preclinical glioblastoma using source analysis.
    Delgado-Goñi T; Ortega-Martorell S; Ciezka M; Olier I; Candiota AP; Julià-Sapé M; Fernández F; Pumarola M; Lisboa PJ; Arús C
    NMR Biomed; 2016 Jun; 29(6):732-43. PubMed ID: 27061401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of MR-Based Metabolomics and Molecular Profiling in the Tumor Microenvironment of Temozolomide-Treated Orthotopic GL261 Glioblastoma in Mice.
    Zhao K; Calero-Pérez P; Bopp MHA; Möschl V; Pagenstecher A; Mulero-Acevedo M; Vázquez M; Barcia C; Arús C; Nimsky C; Rusch T; Bartsch JW; Candiota AP
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of p38 MAPK inhibitor with PD-L1 antibody effectively prolongs survivals of temozolomide-resistant glioma-bearing mice via reduction of infiltrating glioma-associated macrophages and PD-L1 expression on resident glioma-associated microglia.
    Dang W; Xiao J; Ma Q; Miao J; Cao M; Chen L; Shi Y; Yao X; Yu S; Liu X; Cui Y; Zhang X; Bian X
    Brain Tumor Pathol; 2021 Jul; 38(3):189-200. PubMed ID: 34231121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas.
    Enríquez Pérez J; Kopecky J; Visse E; Darabi A; Siesjö P
    BMC Cancer; 2020 Jan; 20(1):7. PubMed ID: 31900109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autophagy-based unconventional secretion of HMGB1 in glioblastoma promotes chemosensitivity to temozolomide through macrophage M1-like polarization.
    Li Z; Fu WJ; Chen XQ; Wang S; Deng RS; Tang XP; Yang KD; Niu Q; Zhou H; Li QR; Lin Y; Liang M; Li SS; Ping YF; Liu XD; Bian XW; Yao XH
    J Exp Clin Cancer Res; 2022 Feb; 41(1):74. PubMed ID: 35193644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful Partnerships: Exploring the Potential of Immunogenic Signals Triggered by TMZ, CX-4945, and Combined Treatment in GL261 Glioblastoma Cells.
    Villamañan L; Martínez-Escardó L; Arús C; Yuste VJ; Candiota AP
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33810611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model.
    Banissi C; Ghiringhelli F; Chen L; Carpentier AF
    Cancer Immunol Immunother; 2009 Oct; 58(10):1627-34. PubMed ID: 19221744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unraveling response to temozolomide in preclinical GL261 glioblastoma with MRI/MRSI using radiomics and signal source extraction.
    Núñez LM; Romero E; Julià-Sapé M; Ledesma-Carbayo MJ; Santos A; Arús C; Candiota AP; Vellido A
    Sci Rep; 2020 Nov; 10(1):19699. PubMed ID: 33184423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Chk1 inhibitor SAR-020106 sensitizes human glioblastoma cells to irradiation, to temozolomide, and to decitabine treatment.
    Patties I; Kallendrusch S; Böhme L; Kendzia E; Oppermann H; Gaunitz F; Kortmann RD; Glasow A
    J Exp Clin Cancer Res; 2019 Oct; 38(1):420. PubMed ID: 31639020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Additive antiangiogenesis effect of ginsenoside Rg3 with low-dose metronomic temozolomide on rat glioma cells both in vivo and in vitro.
    Sun C; Yu Y; Wang L; Wu B; Xia L; Feng F; Ling Z; Wang S
    J Exp Clin Cancer Res; 2016 Feb; 35():32. PubMed ID: 26872471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastrodin Liposomes Block Crosstalk between Astrocytes and Glioma Cells via Downregulating Cx43 to Improve Antiglioblastoma Efficacy of Temozolomide.
    Song Y; Huang Q; Pu Q; Ni S; Zhu W; Zhao W; Xu H; Hu K
    Bioconjug Chem; 2024 Sep; 35(9):1380-1390. PubMed ID: 39180545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AT-0174, a novel dual IDO1/TDO2 enzyme inhibitor, synergises with temozolomide to improve survival in an orthotopic mouse model of glioblastoma.
    Bickerdike MJ; Nafia I; Bessede A; Chen CB; Wangpaichitr M
    BMC Cancer; 2024 Jul; 24(1):889. PubMed ID: 39048947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model.
    Wu J; Waxman DJ
    Cancer Lett; 2014 Oct; 353(2):272-80. PubMed ID: 25069038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of temozolomide for recurrent glioblastoma multiforme.
    Chen C; Xu T; Lu Y; Chen J; Wu S
    Eur J Neurol; 2013 Feb; 20(2):223-30. PubMed ID: 22680781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.